C40.90: Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb

C40.90, malignant neoplasm of unspecified bones and articular cartilage of unspecified limb, is listed as a covered diagnosis in 3 Medicare billing and coding articles that apply to 33 HCPCS Level II codes, including J8999 (Prescription drug, oral, chemotherapeutic, nos), Q0512 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…), Q0511 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 2 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C40.90 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
J8999Prescription drug, oral, chemotherapeutic, nosSpecial coverage instructions apply—1
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSpecial coverage instructions apply—1
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSpecial coverage instructions apply—1
J8530Cyclophosphamide; oral, 25 mgSpecial coverage instructions apply—1
J8597Antiemetic drug, oral, not otherwise specifiedSpecial coverage instructions apply—1
J8610Methotrexate; oral, 2.5 mgSpecial coverage instructions apply—1
J8498Antiemetic drug, rectal/suppository, not otherwise specifiedSpecial coverage instructions apply—1
Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgramSpecial coverage instructions apply—1
Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramCarrier judgment—1
Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgramSpecial coverage instructions apply—1
J1442Injection, filgrastim (g-csf), excludes biosimilars, 1 microgramSpecial coverage instructions apply—1
J1449Injection, eflapegrastim-xnst, 0.1 mgCarrier judgment—1
J1447Injection, tbo-filgrastim, 1 microgramSpecial coverage instructions apply—1
Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mgCarrier judgment—1
Q5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mgCarrier judgment—1
Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mgCarrier judgment—1
J2506Injection, pegfilgrastim, excludes biosimilar, 0.5 mgCarrier judgment—1
Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mgCarrier judgment—1
Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mgCarrier judgment—1
J2820Injection, sargramostim (gm-csf), 50 mcgSpecial coverage instructions apply—1
Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mgCarrier judgment—1
Q5148Injection, filgrastim-txid (nypozi), biosimilar, 1 microgramSpecial coverage instructions apply—1
Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mgCarrier judgment—1
E0783Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.)Special coverage instructions apply$9,917.33–$11,667.45 (NU)1
E0786Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter)Special coverage instructions apply$10,969.75–$11,380.88 (NU)1

8 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C40.90

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C40 diagnoses (Malignant neoplasm of bone and articular cartilage of limbs)

Frequently asked questions

Does Medicare cover C40.90 (Malignant neoplasm of unspecified bones and articular…)?

Medicare covers items and services, not diagnoses. 3 Medicare billing and coding articles list C40.90 as a covered diagnosis for 33 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C40.90?

The Level II codes from the policies most specific to this diagnosis are J8999 (Prescription drug, oral, chemotherapeutic, nos, 1 article); Q0512 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…, 1 article); Q0511 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…, 1 article); J8530 (Cyclophosphamide; oral, 25 mg, 1 article); J8597 (Antiemetic drug, oral, not otherwise specified, 1 article). Code choice depends on the item supplied; check each code's descriptor.

What does Medicare pay for equipment billed with C40.90?

Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.

Which Medicare policy articles list C40.90?

A52479 (Oral Anticancer Drugs - Policy Article); A56748 (Billing and Coding: White Cell Colony Stimulating Factors); A56695 (Billing and Coding: Implantable Infusion Pump).

What is ICD-10-CM code C40.90?

C40.90 is the ICD-10-CM code for malignant neoplasm of unspecified bones and articular cartilage of unspecified limb, in category C40 (Malignant neoplasm of bone and articular cartilage of limbs), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup